BIOCON vs PPLPHARMA: Stock Comparison
BIOCON is the larger company by market capitalisation. BIOCON shows a higher dividend yield, faster revenue growth and a higher net margin, while PIRAMAL PHARMA shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BIOCON leads 6; PPLPHARMA leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BIOCON | PPLPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BIOCON | PPLPHARMA |
|---|---|---|
| Live Price | ₹397.4 | ₹214.22 |
| Day Change | -1.14% | -0.13% |
| Volume | 31.09 L | 26.18 L |
| 52-Week High | ₹447.15 | ₹220.36 |
| 52-Week Low | ₹337.05 | ₹132.3 |
| Distance from 52W High | -11.13% | -2.79% |
Valuation
| Metric | BIOCON | PPLPHARMA |
|---|---|---|
| Market Cap | ₹64,740 Cr | ₹28,438 Cr |
| P/E Ratio | 119.79x | 0x |
| P/B Ratio | 1.91x | 3.49x |
| EPS | ₹0.87 | ₹0.85 |
| Book Value | ₹224.71 | ₹61.31 |
| Dividend Yield | 0.13% | 0% |
Growth
| Metric | BIOCON | PPLPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.3% | -0.1% |
| EPS Growth (TTM YoY) | -72.5% | 0% |
| Qtr Sales Growth | 594.32% | -50.44% |
| Qtr Profit Growth | 162.07% | 263.54% |
Profitability & Leverage
| Metric | BIOCON | PPLPHARMA |
|---|---|---|
| ROE | 1.01% | 8.6% |
| ROCE | 2.42% | 9.1% |
| Net Margin | 2.29% | -3.68% |
| Operating Margin | 8.5% | 20.01% |
| Debt to Equity | 0.4x | 0.09x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BIOCON | PPLPHARMA |
|---|---|---|
| Promoter Holding | 29.73%▼ 0.17 pp | 34.8%▼ 0.06 pp |
| FII Holding | 8.14%▲ 0.62 pp | 12.52%▼ 17.66 pp |
| DII Holding | 23.38%▼ 0.69 pp | 14.57%▼ 1.04 pp |
| Public Holding | 23.75%▲ 0.34 pp | 37.63%▲ 18.62 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BIOCON and PIRAMAL PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.